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Abstract
High-grade serous carcinoma (HGSC) is the most aggressive and predominant form of epithelial 
ovarian cancer and the leading cause of gynecological cancer death. We have previously shown 
that CTCFL (also known as BORIS, Brother of the Regulator of Imprinted Sites) is expressed in 
most ovarian cancers, and is associated with global and promoter-specific DNA hypomethylation, 
advanced tumor stage, and poor prognosis. To explore its role in HGSC, we expressed BORIS in 
human fallopian tube secretory epithelial cells (FTSEC), the presumptive cells of origin for 
HGSC. BORIS-expressing cells exhibited increased motility and invasion, and BORIS expression 
was associated with alterations in several cancer-associated gene expression networks, including 
fatty acid metabolism, TNF signaling, cell migration, and ECM-receptor interactions. Importantly, 
GALNT14, a glycosyltransferase gene implicated in cancer cell migration and invasion, was 
highly induced by BORIS, and GALNT14 knockdown significantly abrogated BORIS-induced 
cell motility and invasion. In addition, in silico analyses provided evidence for BORIS and 
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GALNT14 co-expression in several cancers. Finally, ChIP-seq demonstrated that expression of 
BORIS was associated with de novo and enhanced binding of CTCF at hundreds of loci, many of 
which correlated with activation of transcription at target genes, including GALNT14. Taken 
together, our data indicate that BORIS may promote cell motility and invasion in HGSC via 
upregulation of GALNT14, and suggests BORIS as a potential therapeutic target in this 
malignancy.
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Introduction
Although ovarian cancer accounts for less than 2% of all new cancer cases in American 
women, it is the leading cause of gynecological cancer death, claiming the lives of more than 
half of all women diagnosed within 5 years. The discordance between prevalence and 
prognosis is primarily due to its advanced stage at diagnosis, as over 80% of patients present 
with disseminated cancer that is often resistant or refractory to standard treatment measures. 
HGSC is the most aggressive and most predominant form of epithelial ovarian cancer 
(EOC), making up more than 70% of diagnosed cases. Molecular analysis of a large number 
of HGSC in TCGA uncovered a high frequency of DNA copy number alterations (CNA) and 
almost ubiquitous occurrence of TP53 mutations, as well as a low but statistically significant 
frequency of alterations in BRCA1, BRCA2, NF1, RB1, and CDK12 [1]. Pathway analysis 
implicated defective homologous recombination in approximately half of HGSC and the 
activation of both NOTCH and FOXM1 signaling [1, 2].
Although the ovarian surface epithelium (OSE) was originally thought to contain the cell of 
origin, it is now recognized that most HGSCs originate in secretory cells of the distal 
fallopian tube (fimbriae) and only later metastasize to the ovary. Providing evidence for this 
paradigm shift, a large proportion of patients with HGSC have noninvasive lesions called 
serous tubal intraepithelial carcinoma (STIC) in their fallopian tubes that are histologically 
similar to and carry identical mutations (including TP53) and expression profiles as HGSC 
[3]. STIC has been found in patients who underwent prophylactic salpingo-oophorectomy in 
the absence of any invasive carcinoma but were known carriers of BRAC1/2 predisposition 
mutations [4], indicating that this lesion can predate invasive cancer. Moreover, our previous 
DNA methylome analyses demonstrated that the methylation profile of HGSCs and fallopian 
tube epithelia (FTE) are more similar than are HGSCs and OSE [5]. These findings 
prompted the development of immortalized fallopian tube secretory epithelial cells (FTSEC) 
derived from the fimbrial region as a more physiologically relevant experimental model of 
the disease [6]. The validity of this model was supported by the demonstration that ectopic 
expression of cyclin E1 (CCNE1), which is associated with poor survival in HGSC, 
imparted malignant properties to untransformed fallopian tube epithelial cells when TP53 
function was abrogated, leading to an accumulation of DNA damage and altered 
transcription of DNA damage response genes related to DNA replication stress [7].
Hillman et al. Page 2
Mol Cancer Res. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We have previously shown that BORIS (CTCFL) is expressed in a large proportion of EOC 
and its expression is associated with global genomic DNA hypomethylation and BORIS 
promoter DNA hypomethylation [8]. Importantly, a significant association was found 
between BORIS expression, increased tumor stage, and poor prognosis [9]. BORIS is a 
cancer germline (CG) or cancer testis (CT) antigen gene, primarily expressed in the germline 
under normal circumstances and abnormally activated in many malignancies [10]. Indeed, 
BORIS is one of the most commonly activated CG genes in cancer [11] and has been 
proposed as an activator of other CG genes [12], making it an attractive immunotherapy 
target [13].
BORIS is the sole paralog of CTCF (CCCTC-binding factor), a multifunctional DNA 
binding protein [14]. BORIS and CTCF share high homology in their central zinc finger 
core and can potentially bind identical or similar DNA sequences; however, ChIP-seq 
experiments in cancer and germ cells have shown that BORIS binds only a subset of CTCF 
binding sites [15] actually consisting of two closely located CTCF binding motifs (termed 
2xCTSes) either as a CTCF-BORIS heterodimer or a BORIS homodimer [15]. The 2xCTSes 
are generally enriched in active chromatin marks including H3Kme2, H3Kme3, H3K27ac, 
H3K79me2 and H3K9ac, in addition to the histone variant H2A.Z [15, 16]. Unlike single-
motif CTCF target sites (1xCTSes), which are suggested to have insulator function, 
2xCTSes are preferentially found at regions of open chromatin such as active promoters and 
enhancers, in both cancer and germ cells [15]. Interestingly, 2xCTSes are also enriched in 
genomic regions that escape the replacement of histones by protamines in human and mouse 
sperm [15].
Despite the high degree of similarity in their DNA binding domains, the N- and C-terminal 
domains of CTCF and BORIS are highly divergent suggesting that, once bound, these two 
proteins may elicit distinct effects [14]. CTCF is highly conserved, ubiquitously expressed, 
and essential for normal development, as evidenced by embryonic lethality of whole body 
CTCF knockout in mice [17]. Documented roles for CTCF include widespread 
transcriptional regulation, genomic imprinting, chromatin domain insulation, and X-
chromosome inactivation (reviewed in [18]). The multifunctionality of CTCF often hinges 
on its utility as an architectural protein, maintaining genomic stability and facilitating gene 
regulatory interactions through chromosome loop formation in conjunction with the cohesin 
complex [19]. In contrast to CTCF, the function(s) of BORIS in the male germline and in 
cancer cells is less established. The exclusive expression of BORIS in the male germline, 
and defective spermatogenesis in BORIS knockout mice, suggest that the normal function of 
BORIS is to regulate male germ cell development. This function may be due to its regulating 
expression of the important testis-specific genes Gal3st and Prss50 [15, 20, 21] possibly by 
cooperating with CTCF (at 2xCTSes) and other testis-specific transcription factors [22]. In 
cancer, BORIS has been proposed to be an oncogene with various studies demonstrating its 
activity in repressing tumor suppressor genes including CTCF and inducing other oncogenes 
[23]. BORIS has been shown to induce pro-tumorigenic phenotypes in cell line models [24–
26], including increased cellular proliferation [27–29] and invasion [26, 29]. Although the 
mechanism(s) of action of BORIS is still being elucidated, it may function in a dominant-
negative fashion by displacement of CTCF and the reorganization of the chromatin 
landscape [15, 30] thus impacting gene expression and contributing to the cancer phenotype. 
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Consistent with this idea, our previous studies showed that an elevated BORIS/CTCF 
expression ratio correlated with disease progression in ovarian cancer [9].
In the current study we assessed the phenotypic and molecular changes that BORIS 
expression imposes on a physiologically relevant model of HGSC precursor cells. BORIS 
was expressed in FT282 cells, an immortalized non-transformed cell line derived from 
FTSEC, the proposed initiating cells of many HGSCs [7]. Ectopic expression of BORIS in 
FT282 cells induced changes indicative of cellular transformation including increased 
migration and invasion through Matrigel. Phenotypic changes were accompanied by 
significant alterations in gene expression and alteration of key cancer associated pathways. 
In particular, BORIS induced expression of the cancer-associated glycosyltransferase 
GALNT14 gene, which contributed to the downstream invasive phenotype. Moreover, 
BORIS was directly implicated in many of the observed gene expression changes, as its 
binding was enriched at differentially expressed genes (DEGs). Finally, ectopic expression 
of BORIS in FT282 cells was associated with both quantitative and qualitative increases in 
genomic CTCF binding. Taken together, our results support a role for BORIS in increasing 
the invasive potential of HGSC precursor cells. These data, coupled with widespread 
increased expression of BORIS in HGSC, suggests that BORIS is a potential therapeutic 
target in this malignancy.
Materials and Methods
FTE cell culture and ectopic BORIS expressing cell line
A clonal derivative of FT282 was generated a previously described [31], and cultured in 
DMEM/Ham’s F-12 50/50 Mix (DMEM:F12) without L- glutamine (Corning) with 10% 
FBS (Peak Serum) and 1% Penicillin-Streptomycin (Gibco). To generate a BORIS 
expressing FT282 cell line, a CpG-free BORIS cDNA [15] was cloned into SparQ IRES 
lentivector containing green fluorescent protein (GFP) (System Biosciences). FT282 cells 
were transduced with BORIS containing lentivirus or empty vector (EV) in the presence of 
8μg/mL polybrene. Infected cells were propagated for 14 days and sorted to obtain GFP 
positive cells containing lentivirus.
Protein extraction and western blotting
Cells at approximately 80% confluency in 6 well plates were washed 2x with 1ml ice-cold 
PBS containing protease inhibitors (Pierce™ Protease Inhibitor Mini Tablets, EDTA Free) 
and lysed in 150μl, high-salt RIPA buffer (50mM Tris-HCl pH 7.4, 0.5M NaCl, 0.25% 
Deoxycholic acid, 1% NP-40, 1mM EDTA, 0.1% SDS) containing protease inhibitors. 
Lysates were sonicated on ice for two 15 second intervals with cooling between cycles. 
Samples were vortexed and quantified using the Pierce BCA Protein Assay Kit (Thermo 
Fisher Scientific). Twenty (20) μg of protein was prepared with 1% β-mercaptoethanol and 
1x lithium dodecyl sulfate (LDS) sample buffer (NuPAGE), separated by SDS-PAGE and 
transferred to PVDF membranes (Bio-Rad). Membranes were blocked with 5% nonfat dry 
milk (NFDM) in 0.1M PBS containing 0.1% Tween-20 (PBST) and incubated with primary 
antibody overnight in 5% NFDM at 4°C. Membranes were washed 3x in PBST (8 minutes 
each at RT). Membranes were then incubated with secondary antibody diluted in 5% NFDM 
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for 1 hour at RT, followed by three washes in PBST. The signal was detected using Pierce™ 
ECL Western Blotting Substrate (Thermo Fisher Scientific) and images captured on the Bio-
Rad ChemiDoc Touch Imaging System. Primary antibodies were anti-human BORIS mouse 
monoclonal antibody (1:1000) [15], GALNT14 rabbit polyclonal antibody (1:1000) 
(Proteintech: 16939-1-AP) and ACTB mouse monoclonal (1: 10,000) (Sigma). Anti-mouse 
(#55550) and anti-rabbit (#55676) secondary antibodies were from MP Biomedical. 
Secondary antibodies were used at a 1:2000 dilution.
Proliferation assays
Cells were grown in 100 μl of complete medium in 96 well plates. Eight (8) technical 
replicates for each cell line/treatment were seeded onto 5 separate plates, one for each time 
point. Every 24 hours one plate was processed. The Sulforhodamine B (SRB) assay was 
carried out as described [32].
Transwell migration and invasion assays
FT282-BORIS and FT282-EV cells were grown to 60% confluency in complete medium; 24 
hr prior to trypsinization the medium was replaced with serum-free medium (DMEM:F12 
+ 1% Penicillin-Streptomycin). Fifty thousand (5X104) cells in 500μl serum-free media 
were pipetted into the top of transwell inserts (8 micron pores, BD Biosciences) in a 24 well 
plate. Five hundred (500) μl of complete medium (chemoattractant) was pipetted into the 
bottom chamber. After 18 hours, cells were removed from the top surface of the membrane 
with a cotton swab and inserts fixed in 100% methanol, washed and stained in 0.2% crystal 
violet. Dried membranes were mounted onto glass slides for microscopic evaluation. 
Experiments were performed in triplicate transwells and quantified by averaging the number 
of cells per 20x field of view counting 4 fields per chamber. Invasion assays were carried out 
in a similar manner except inserts coated with Matrigel were used and assays were carried 
out for 22 hours.
Propidium Iodide staining/cell cycle analysis
Approximately 2X106 cells were washed twice in cold PBS and resuspended in 300 μl of 
PBS. Cells were fixed by adding 700 μl of 100% ethanol (EtOH) dropwise while vortexing. 
Fixed cells were stored at −20°C until staining was performed. Cells were washed in PBS 
and stained with 50 μg/ml propidium iodide at 4°C for 1 hour, passed through a 0.2 micron 
filter and analyzed on an LSR Fortessa A. instrument. Cell cycle analysis was done using 
ModFit 4.1.
RNA-sequencing, DEG identification, and pathway analysis
Sequencing libraries were prepared from 1μg total RNA using the TruSeq Stranded Total 
RNA kit (Illumina). Library preparation, sequence enrichment and sequencing were carried 
out by the RPCCC Genomics Shared Resource using an Illumina HiSeq2500. FASTQ files 
were mapped to the UCSC Human reference (build hg19) using TopHat2 with the default 
parameter setting of 20 alignments per read and up to two mismatches per alignment. The 
aligned reads (BAM files) were then analyzed with Cufflinks 2.0.0 to estimate transcript 
relative abundance using the UCSC reference annotated transcripts (build hg19). The 
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expression of each transcript was quantified as the number of reads mapping to a transcript 
divided by the transcript length in kilobases and the total number of mapped reads in 
millions (FPKM). GO analysis was performed in R 3.5.1 with clusterProfiler 3.8.1. 
Biological process annotation was performed with the enrichGO() command and redundant 
annotations were collapsed with simplify(up_ego, cutoff=0.7, by=“p.adjust”, 
select_fun=min) prior to plotting. Full GO results are provided in Supplementary Table 2. 
Significantly dysregulated genes (p<0.006, logFC> |0.25|), were then tested for pathway 
enrichment utilizing DAVID (https://david.ncifcrf.gov) and the KEGG database (http://
www.genome.jp/kegg/) and the Reactome (https://reactome.org/) database. Complete RNA-
seq data is available in GEO under accession number GSE131931.
Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
One microgram (1μg) of DNase-treated RNA was converted to cDNA using the iSCRIPT 
Advanced cDNA Synthesis Kit (Bio-Rad). cDNA was diluted 1:10 with water for use in 
subsequent RT-qPCR reactions. RT-qPCR was performed using the CFX96™ Real-Time 
PCR Detection System (Bio-Rad) with SsoAdvanced™ Universal SYBR® Green Supermix 
(Bio-Rad). Primers used for qPCR were designed using Beacon Designer (Premier Biosoft) 
and sequences included in Supplmentary Table 7. HPRT1 mRNA levels were assayed as an 
endogenous control.
siRNA knockdown of GALNT14
Knockdown of GALNT14 was by transient transfection of Silencer® Select siRNA targeted 
against GALNT14 (ThermoFischer Scientific, assay s35936); the Silencer® Select Negative 
Control No. 1 was used as a baseline control. Cells were grown to approximately 80% 
confluency in 6 well dishes. For each transfection 3μl of Lipofectamine RNAiMAX reagent 
was added to 150μL of Opti-MEM medium followed by 30 pmol of siRNA. The diluted 
siRNA (150μL) was added to the diluted Lipofectamine RNAiMAX reagent and incubated 
for 5 minutes in a heat block at 23°C. Two hundred-fifty (250μL) of the siRNA 
Lipofectamine RNAiMAX complex was then added dropwise to the cells. Cells were 
harvested for protein 48 hours after transfection and GALNT14 knock down was confirmed 
by western blot.
ChIP-sequencing
ChIP-seq and bioinformatics analysis was performed essentially as described using 
approximately 108 cells [15]. Formaldehyde-fixed chromatin was sheared to 200– 500 bp 
(Bioruptor), incubated overnight with DiaMag magnetic beads (Diagenode, Inc.) and CTCF 
or BORIS monoclonal or polyclonal antibodies [15] and DNA isolated from precipitated 
chromatin. ChIP DNA was amplified using a TruSeq ChIP Sample Preparation Kit 
(Illumina, Inc., USA) and used for single end sequencing on an Illumina Genome Analyzer. 
Sequences were aligned with Bowtie and peaks called using MACS; the Peak Splitter was 
used to call sub-peaks and summits of peaks and improve peak resolution. ChIP-seq data 
were visualized using IGV. Peak overlaps between CTCF and BORIS ChIP-seq data sets 
were determined with BedTools Suite. Peaks were defined as overlapping if at least 1 bp of 
reciprocal peaks intersect (CTCF&BORIS); the remaining peaks were defined as non-
overlapping (CTCF-only and BORIS-only). Normalized tag density profiles were generated 
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using the BedTools coverage option from the BedTools Suite, normalized to the number of 
mapped reads, and plotted in Microsoft Excel. The heatmaps were generated using the 
seqMINER 1.3.3. We used either k-means ranked or linear method for clustering 
normalization. The summits of either CTCF or BORIS peaks were extended ±5 kb. 
seqMINER was also used to generate the average profiles of read density for different 
clusters. Position weight matrices for CTCF and BORIS bound regions were searched using 
Multiple EM for Motif Elicitation (MEME). The sequences under the summit of either 
CTCF or BORIS peaks extended 100 bp upstream and downstream were used for motif 
discovery. We ran MEME with parameters (− mod oops-revcomp -w 20) to identify 20-bp-
long motifs considering both DNA strands. To analyze the occurrence of CTCF motifs in the 
sequences occupied by CTCF or BORIS, or both proteins, FIMO software (MEME suite) 
was employed with default parameters. The position weight matrices found for CTCF 
binding regions by MEME were used for FIMO software. Each CTCF motif occurrence had 
a p value < 0.0001 in the sequences of 200 bp around the summit of either CTCF (CTCF-
only, CTCF&BORIS bound regions) or BORIS (BORIS-only bound regions) peaks. 
Genomic distribution of CTCF and BORIS ChIP-seq peaks relative to reference genes was 
performed using the Cis-regulatory Element Annotation System (CEAS). Complete ChIP-
seq data is available in GEO under accession number GSE131931.
Results
BORIS expression in epithelial ovarian cancer (EOC) correlates with increased stage and 
decreased survival
We previously showed that BORIS expression in EOC correlated with advanced tumor stage 
and decreased survival; interestingly, this correlation was even more significant when the 
ratio of BORIS/CTCF mRNA expression was used in the analysis. Furthermore, a 
significant correlation was observed between BORIS promoter hypomethylation, increased 
tumor stage and poor prognosis [9]. To corroborate these findings in an independent and 
larger dataset, we queried CSIOVDB (Ovarian Cancer Database of Cancer Science Institute 
Singapore), a microarray-based gene expression database of EOC [33]. Analyses showed 
that BORIS expression is significantly higher in fallopian tube carcinoma (“FTE tumors”) 
and ovarian carcinomas (“Tumors”) compared to normal fallopian tube epithelium (FTE) 
and ovarian surface epithelium (OSE) (Supplementary Fig. 1). Moreover, BORIS expression 
is highest in serous tumors compared to other EOC subtypes (Supplementary Fig. 2A). 
Consistent with our previous findings, BORIS expression was significantly higher in 
advanced stage (Fig. 1A) and higher-grade tumors (Supplementary Fig. 2B). A similar 
analysis of 47 ovarian cancer cell lines in the Cancer Cell Line Encyclopedia (CCLE) 
showed no significant differences in levels of BORIS expression across histological subtypes 
from which the cell lines were derived (Supplementary Fig. 2C); stage and grade 
information was not available. Also consistent with our earlier study, BORIS expression 
correlated with reduced disease-free and overall survival (Fig. 1B). When the ratio of 
BORIS:CTCF expression was used in these analyses, the same associations were observed 
(Supplementary Fig. 3). We also analyzed RNA-seq data from The Cancer Genome Atlas 
(TCGA) and found that ovarian cancers (i.e. HGSC) exhibited the highest expression of 
BORIS compared to other cancers (data not shown). However, no correlation was observed 
Hillman et al. Page 7
Mol Cancer Res. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
between BORIS mRNA expression, or BORIS:CTCF mRNA expression ratio, and overall 
survival in HGSC (Supplementary Fig. 4). This was also true when TCGA microarray 
expression data was used (not shown). The discrepancy between CSIOVDB and TCGA is 
likely explained by the fact that CSIOVDB data contains all EOC subtypes while TCGA 
data is composed solely of HGSC. Indeed, when similar analysis was carried out using only 
the serous carcinoma samples in CSIOVDB, no correlation with survival was observed 
(Supplemental Fig.5) consistent with increased expression of BORIS in HGSC 
(Supplementary Fig. 2A).
Ectopic expression of BORIS in FTE cells induces cellular changes typical of cellular 
transformation
To determine the impact of ectopic BORIS expression in a physiologically relevant in vitro 
model of HGSC, we employed a clonal derivative of the immortalized, non-transformed 
human fallopian tube epithelial cell line, FT282 originally described by Karst et al. [7]. The 
FT282 cell line was established from normal human FTE cells immortalized with the 
catalytic subunit of human telomerase, telomerase reverse transcriptase (TERT) and carrying 
mutant TP53R175H, a dominant negative mutation, as TP53 mutations are ubiquitous in 
early stages (i.e. STICs) of HGSC transformation [34]. A clonal derivative of FT282 cells 
(FT282-c11)[31] was infected with the SparQ IRES lentivector-GFP containing a BORIS 
cDNA or the empty vector (EV) and cells sorted for GFP to enrich for infected cells. 
Western blot analyses confirmed high BORIS protein expression in FT282-BORIS, but not 
FT282-EV cells (Fig. 2A).
To address whether BORIS expression induced phenotypic changes associated with 
transformation, FT282-BORIS and FT282-EV cells were assayed for changes in cellular 
morphology, proliferation, migration and invasion. Microscopic evaluation failed to reveal 
differences in morphology between FT282-BORIS and FT282-EV cells (Supplementary Fig. 
6A) and their appearance was similar to that of early passage immortalized FTSECs [6]. 
BORIS expression did not alter cellular proliferation, as assayed by the SRB assay 
(Supplementary Fig. 6B) or the MTS assay (not shown). However, cell cycle analysis (Fig. 
2B) demonstrated that FT282-BORIS cells had a significantly smaller proportion of cells in 
G1 compared to FT282-EV cells (p = 0.02), a slightly larger (but not statistically significant) 
proportion of cells in S-phase (p = 0.32), and more than twice the proportion of cells in 
G2/M (p = 0.0014), suggesting cell cycle arrest at the G2/M checkpoint (Fig. 2C). Notably, 
cell migration was significantly enhanced in the FT282-BORIS cells as assayed by transwell 
migration assays (Fig. 2D); furthermore, FT282-BORIS exhibited twice the level of invasion 
through Matrigel compared to the FT282-EV control (Fig. 2E). Taken together, these results 
indicate that BORIS expression changed the behavior of FT282 cells, driving them towards a 
transformed phenotype.
Ectopic BORIS expression modulates expression of cancer-associated genes and 
pathways
During spermatogenesis BORIS acts as a transcriptional regulator of several essential testis-
specific genes, Gal3st and Prss50 [15, 20]. To access the impact of ectopic BORIS 
expression in FTE cells, we performed RNA-sequencing (RNA-seq) analysis in FT282-
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BORIS cells compared to the FT282-EV control which revealed substantial differences in 
gene expression between the cell populations (Fig. 3A). The total number of differentially 
expressed genes (DEGs) in FT282-BORIS compared to FT282-EV was 1656, including 773 
genes significantly upregulated and 883 genes significantly downregulated (p < 0.006)
(Supplementary Table 1). To gain insight into the functional significance of these changes, 
we performed gene ontology (GO) analysis. Consistent with the increase in migration 
observed in FT282-BORIS cells, upregulated genes were significantly enriched for 
biological processes including “regulation of chemotaxis” and “positive regulation of cell 
migration” while downregulated genes were enriched for processes such as “extracellular 
matrix organization” and “cell-substrate interaction” (Fig. 3B, Supplementary Table 
2).These observations suggest that BORIS enhances FT282 cell motility by upregulating 
positive regulators of cell motility and downregulating genes involved in cell adhesion.
It might be anticipated that the more differentially expressed genes in a biological process 
may be driving identification of the GO category. Using this criterion, a number of genes 
from several different GO categories (Supplemental Table 2) were chosen to validate the 
RNA-seq data using RT-qPCR. These included 6 genes upregulated in BORIS-expressing 
cells, GALNT14 and CHSY3 (glycoprotein biosynthesis), SERPINB2 and PCOLCE2 
(regulation of peptidase activity), ITGA4 (positive regulation of cell migration), and CXCL2 
(regulation of cell migration and chemotaxis), as well as 4 genes downregulated in FT282-
BORIS cells, KLK5 (ECM organization), SFRP1 and IGFBP5 (gland development), and 
BCAM (cell substrate adhesion). All 6 upregulated genes were validated by RT-qPCR (Fig. 
3C), while 3 of 4 of the downregulated genes also exhibited decreased expression by RT-
qPCR (Fig. 3D); IFGBP5 did not validate possibly because of cross reaction with other 
IGFBP gene family members.
KEGG pathway analysis revealed several cancer-associated pathways significantly impacted 
by ectopic BORIS expression (Supplementary Table 3). In this analysis, the pathway for 
biosynthesis of unsaturated fatty acids was the most enriched for DEGs upregulated in 
FT282-BORIS cells; fatty acids are essential for cancer cell proliferation due to a high 
demand for lipids [35]. Consistent with this, several downregulated genes are involved in 
fatty acid degradation. In addition, the tumor necrosis factor (TNF) signaling pathway was 
amongst the most highly upregulated. The NF-kappa-B (NFKB) signaling pathway, which is 
activated by proinflammatory cytokines, including those in the TNF pathway was also 
significantly upregulated as well as the cytokine-cytokine receptor interaction and the 
rheumatoid arthritis pathway. Among pathways enriched for genes downregulated in FT282-
BORIS cells were genes involved in signaling of the p53 tumor suppressor gene. Notably, a 
separate pathway analysis using the Reactome database also identified several inflammatory 
pathways including interleukin-10 signaling, chemokine receptors, and the inflammasome 
pathway as enriched in upregulated genes in FT282-BORIS cells, as well as several 
pathways related to p53 signaling enriched for downregulated genes (Supplementary Table 
4). Consistent with the observed increases in migration and invasion, several related 
pathways were also enriched for DEGs; for example KEGG pathways for adherens junction 
and focal adhesion were enriched for a large number of genes downregulated in FT282-
BORIS cells, some of which (e.g. WASF3, ACTN2, TCN, VCL, ZYX) are known to 
enhance cell motility or metastasis when lost in certain cell types (for example [36]). Among 
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upregulated genes, the “Mucin type O-Glycan biosynthesis” pathway was significantly 
enriched in the KEGG analysis (Supplementary Table 3). Similarly, analysis of upregulated 
DEGs in the Reactome database revealed enrichment in pathways for “O-linked 
glycosylation of mucins” (Supplementary Table 4). Abnormal glycosylation, which is often 
attributed to deregulated expression of glycosytransferases, is a common feature of human 
cancers and affects a number of cellular properties including proliferation, apoptosis, 
differentiation, migration, invasion, transformation, and immune responses [37]. Thus, 
BORIS expression in normal FTE cells resulted in a deregulation of multiple cell pathways 
related to cancer development and progression.
BORIS induces expression of GALNT14 in FTE cells which contributes to the migratory 
and invasive phenotype
GALNT14, a member of the Mucin type O-Glycan biosynthesis pathway, was the most 
highly induced gene (log2 [fold change] = 5.85) (Supplementary Table 1), a finding 
confirmed by RT-qPCR (Fig. 3C). Western blot analysis confirmed that GALNT14 protein 
was also significantly upregulated in FT282-BORIS cells compared to FT282-EV (Fig. 4A). 
In addition, we found that BORIS and GALNT14 were co-expressed in several cancer 
datasets, providing further evidence for a link between these two genes (Supplementary 
Table 5).
Based on the transcriptional induction of GALNT14, and its proposed involvement in cancer 
cell migration and invasion in ovarian cancer [38], we sought to determine if the BORIS-
associated increase in cellular migration and invasion was related to the observed increase in 
expression of GALNT14. FT282-BORIS cells were transfected with siRNA targeted against 
GALNT14 mRNA, or with a non-targeting negative control. GALNT14 protein was 
markedly reduced by siRNA knock-down (KD) (Fig. 4B) and this correlated with 
significantly decreased migration (Fig. 4C), supporting the notion that the GALNT14 
glycosyltransferase is involved in the BORIS associated increase in cell motility. Moreover, 
KD of GALNT14 significantly diminished the ability of FT282-BORIS cells to invade 
through Matrigel compared to the negative control (Fig. 4D). These results implicate 
GALNT14 as a contributor to BORIS-induced cellular and molecular changes in FT-282 
cells. Taken together, these results corroborate previous studies implicating BORIS in 
upregulation of inflammatory genes and pathways [15] as well as provide a novel link 
between BORIS expression and aberrant o-linked glycosylation of mucins, which may 
function in cell migration and invasion.
BORIS binding is enriched at the promoters of deregulated genes
In order to investigate the genomic targets of ectopically expressed BORIS, and to compare 
BORIS binding with CTCF occupancy, we performed genome-wide ChIP sequencing 
(ChIP-seq) in FT282-BORIS and FT282-EV cells. ChIP-seq identified a total of more than 
47,000 CTCF binding sites (ChIP-seq peaks) in the two cell populations with 95% present in 
both FT282-BORIS and FT282-EV cells. In addition, almost 24,000 BORIS peaks were 
identified in FT282-BORIS cells (Fig. 5A, left-hand panel). Overlapping of CTCF and 
BORIS ChIP-seq peaks in FT282-BORIS cells revealed three classes of differential 
occupancy: 29,112 sites bound by CTCF alone (CTCF-only), 15,513 sites bound by both 
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CTCF and BORIS (CTCF/BORIS shared), and 8,140 sites bound by BORIS alone (BORIS-
only) (Fig. 5A, right-hand panel). In a previous study using three cancer cell lines that 
express BORIS endogenously, we showed that BORIS preferentially binds and forms 
CTCF-BORIS heterodimers at 2xCTSes [15]. Thus, to determine if ectopically-expressed 
BORIS in FT282-BORIS cells was also associated with 2xCTSes, we carried out CTCF 
motif analysis using FIMO (MEME suite) within the sequence 100 bp upstream and 
downstream of the summit of the top 1000 CTCF, CTCF/BORIS shared or BORIS (BORIS-
only) peaks (Fig. 5B, left-hand panel). More than one CTCF motif was identified under 53% 
of BORIS-only peaks and 42% of CTCF/BORIS shared peaks compared to only 12% for 
CTCF-only peaks (Fig. 5B, right-hand panel), thus confirming previous findings that BORIS 
preferentially occupies 2xCTSes either together with CTCF or alone. Also in agreement 
with previous work [15], BORIS binding in the FT282-BORIS cell line was enriched at 
promoter regions (defined as plus or minus 2kb from the transcription start sites [TSS]), 
while CTCF-only sites were relatively depleted at promoters and comparatively enriched at 
intergenic regions (Fig. 5C). Consistent with this, and in contrast to CTCF alone, BORIS 
preferentially bound to CpG islands (CGI) (Fig. 5D). Compared to genes not affected by 
BORIS expression, binding of BORIS was significantly enriched at both upregulated and 
downregulated DEGs, 83% and 61% respectively (Fig. 5E) suggesting direct involvement of 
BORIS in gene regulation at these loci. Importantly, upregulation of GALNT14 was 
accompanied by BORIS binding at sites within the promoter and gene body (Fig. 5F). 
Similarly, upregulation of BIRC2, a component of the TNF signaling pathway, was 
accompanied with increased binding of BORIS at its promoter (Supplementary Fig. 8). 
Taken together, these results further demonstrate that, when aberrantly expressed, BORIS 
binds to a subset of CTCF bound sites (CTCF/BORIS), as well as a number of sites not 
bound by CTCF (BORIS-only). Moreover, comparison of BORIS binding and RNA-seq data 
suggests that, in many cases, BORIS is influencing the transcription of DEGs as a 
consequence of direct promoter occupancy.
CTCF ChIP-seq in the FT282-BORIS and FT282-EV lines also suggested a second 
mechanism beyond competition at CTCF binding sites by BORIS at genomic loci already 
bound by CTCF. Compared to FT282-EV cells, more than 500 loci in BORIS expressing 
cells exhibited enhanced binding of CTCF, defined as a tag density more than three times 
higher in BORIS expressing cells compared to FT282-EV (Supplementary Fig. 7). In some 
cases, CTCF binding was clearly evident in FT282-BORIS cells but undetectable in BORIS-
EV cells and thus appeared as “new” CTCF-binding sites (Fig. 5F, Supplementary Fig. 8). 
For example, the GALNT14 gene showed increased CTCF binding at its promoter and a 
novel CTCF binding site in the gene body (Fig. 5F), indicating that increased CTCF 
occupancy may be important for its increased expression in FT282-BORIS cells. 
Interestingly, only about 50% of these new or enhanced CTCF binding sites were also bound 
by BORIS in FT282-BORIS cells. These new or enhanced CTSes appeared to be nonrandom 
with respect to genomic location. More than two-thirds (382/561) of them overlap with 
known genes, 74 of which are DEGs. Fifty-three (53) of these 74 (~72%) DEGs were 
upregulated at the mRNA level in FT282-BORIS cells, while 21 (~28%) were 
downregulated (Supplementary Table 6). This phenomenon indicates that BORIS binding 
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may lead to a more open chromatin conformation at upregulated DEGs by making these 
regions more accessible to CTCF binding.
Discussion
Identification of oncogenic drivers of HGSC is expected to lead to new therapeutic targets in 
this malignancy. Our earlier findings that expression of BORIS was positively correlated 
with advanced stage disease and poor prognosis of ovarian cancer patients [9] suggested that 
this CT gene might be an oncogene in this malignancy. Here, we corroborated these findings 
by showing in an independent dataset (CSIOVDB), that BORIS expression is highly 
expressed in HGSC and correlates with advanced stage and reduced disease-free and overall 
survival. The correlation is even more significant when the ratio of BORIS/CTCF mRNA is 
used in the analysis possibly reflecting the competitive nature of BORIS and CTCF binding.
Expression of BORIS in human FT282 cells, a physiologically relevant cell culture model of 
HGSC precursor cells in the fallopian tube [6, 7] resulted in enhanced cellular migration and 
invasion. Changes in cell cycle progression were also observed, as BORIS expression led to 
cell cycle arrest at G2/M. Since CTCF has previously been shown to regulate cell cycle 
progression [39, 40] it might be anticipated that this function could be impaired by BORIS-
induced disruption of CTCF regulation at key cell cycle genes. Moreover, this phenotype is 
consistent with previous studies linking BORIS expression to deregulation of the cell cycle 
[26]. Alternatively, cell cycle arrest in BORIS expressing cells may reflect DNA damage due 
to disruption of CTCF function in limiting oxidative stress [41]. Related to this, RNA-seq 
analysis indicated a significant upregulation in ataxia telangiectasia mutated (ATM) mRNA 
in BORIS expressing cells [42]. There was also significant upregulation of genes involved in 
inflammatory pathways and the O-linked glycosylation of mucins, including a more than 50-
fold (RNA-seq) upregulation of GALNT14, a glycosyltransferase with an established link to 
ovarian and breast cancer cell migration [38, 43]. siRNA knockdown of GALNT14 partially 
abrogated both cellular migration and invasion in FT282-BORIS cells, supporting its role as 
a downstream effector of these BORIS-induced phenotypes. Importantly, based on ChIP-seq 
analysis, GALNT14 is a direct target of BORIS. Although BORIS and GALNT14 
expression appears to be correlated in several other cancer types, this association was not 
observed in primary HGSC (Supplementary Table 5). One possibility for this inconsistency 
is that BORIS regulates GALNT14 expression only early on in HGSC progression; 
alternatively, BORIS and GALNT14 may be co-expressed in only a subset of tumor cells, 
similar to the intratumor heterogeneity observed previously for other CT genes [44]. 
GALNT14, and most of the other genes examined by RT-qPCR (Fig. 3C&D), exhibited co-
expression (i.e. maintained high log odds ratios in co-occurrence and mutual exclusivity 
analysis, cBioPortal) in TCGA ovarian cancer expression data. This is consistent with our 
finding that all but one of these genes (CXCL2) bound BORIS and CTCF at their promoter 
regions and/or at intragenic regions in BORIS-expressing FT282 cells. Despite this, only 
expression of CHSY3 and SERPINB2 (both upregulated) mirrored BORIS expression with 
respect to increased expression in later stage and higher grade tumors in the CSIOVDB 
database; similarly, only increased expression of CHSY3 and SERPINB2 correlated with 
either overall or disease-free survival (Supplemental Fig. 9) similar to BORIS expression 
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(Fig. 1). It may be that other BORIS transcriptional targets, or the overall chromatin state 
induced by BORIS, are driving the survival association for BORIS.
In some contexts, BORIS has been implicated in the activation of other CT antigen (CTA) 
genes [12, 45]; however, in our study only 26 of 1019 identified CTA genes [11] were 
significantly upregulated in FT282-BORIS cells (not shown), a finding consistent with other 
studies that have failed to verify BORIS-mediated induction of CT genes [46, 47]. BORIS 
expression had no detectable effect on FT282 cell proliferation. This might be explained by 
the unique pattern of progression of ovarian cancer, in that initial cellular transformation 
may begin in the FTE, but the ovary is often the site of the overt cancerous mass, suggesting 
that transformed cells of the FTE may in some instances acquire a migratory and invasive 
phenotype before they metastasize to the ovary and begin to proliferate at an increased rate.
ChIP-sequencing revealed that BORIS preferentially bound at gene promoters and CGI, with 
this tendency strongest for BORIS-only sites. In addition, BORIS binding was more likely to 
be found at BORIS-induced DEGs, implicating BORIS in a direct regulatory role of these 
loci. Although ChIP-seq analyses of FT282 cells or its derivatives for histone modifications 
and other transcription factors have yet to be carried out, it is likely that BORIS binding sites 
co-localize with active chromatin marks such as H3Kme2, H3Kme3, H3K27ac, H3K79me2 
and H3K9ac, in addition to the histone variant H2A.Z, as observed in other cell systems [15, 
16].
Interestingly, we identified more than 500 CTCF binding sites in FT282-BORIS cells that 
were either undetectable in FT282-EV cells or exhibited enhanced binding in BORIS 
expressing cells. Roughly half of these sites were also bound by BORIS suggesting that, at 
least for these sites, binding of BORIS may provoke a more open chromatin conformation 
that facilitates CTCF binding. For the remaining new or enhanced CTCF sites that do not 
exhibit binding of BORIS it is possible that a similar mechanism is in play but occurred very 
early after the in0duction of BORIS expression where BORIS functioned in a “hit and run” 
fashion. The mechanism by which BORIS facilitates new or increased binding of CTCF is 
unknown. Consistent with evidence that BORIS binding is less sensitive to methylation [48], 
it is possible that BORIS promotes DNA demethyation at these regions, thereby allowing 
CTCF binding, as previously shown for other loci [12, 27] perhaps by recruitment of TET 
proteins and conversion of 5mC to 5hmC [49]. An alternative mechanisms may be that 
BORIS acts as a pioneer factor at these sites, either allowing CTCF to bind via protein-
protein interactions, or recruiting chromatin remodelers that reposition nucleosomes to allow 
CTCF binding[50].
In summary, our results provide evidence supporting a pro-tumorigenic role for BORIS in 
HGSC. In FT282 cells, ectopic BORIS expression significantly increased cellular migration 
and invasion, deregulated the cell cycle, and significantly altered gene expression. We 
provide further support for BORIS as an important mediator of inflammation as has 
suggested previously and confirm that BORIS binding is not uniform across CTCF sites. 
Relevant future investigations of BORIS related oncogenic mechanisms should include the 
process by which CTCF binding is altered and the function of aberrant O-linked 
glycosylation of mucins.
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Implications
These studies provide evidence that aberrant expression of BORIS may play a role in the 
progression to HGSC by enhancing the migratory and invasive properties of FTSEC.
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Figure 1. BORIS expression correlates with increased tumor stage and reduced survival in 
CSIOVDB.
(A) Analysis of tumor stage. BORIS expression is significantly higher in stage III and IV 
tumors compared to stage I and II tumors. Units on the vertical axis represent normalized 
intensity. Statistical analysis by Mann Whitney test. (B) Kaplan-Meier analysis of patient 
samples partitioned into two groups based on the median expression of BORIS. Left-hand 
curves show disease-free survival (n = 708); right-hand curves show overall survival (n 
=810).
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Figure 2. Ectopic expression of BORIS in FT282 cells results in cell cycle arrest, increased 
cellular motility, and greater invasion capability.
FT282 cells were transduced with a lentivirus containing a CpG-free BORIS cDNA, or with 
the empty vector, grown for 14 days and enriched for GFP expressing cells by FACS. (A) 
Western blot analysis using antibodies to BORIS or β-actin (ACTB). (B) Approximately 
2X106 FT282-EV or FT282-BORIS cells were fixed in ethanol, stained with propidium 
iodide and analyzed on a LSR Fortessa instrument; representative FACS profile of DNA 
content (propidium iodide staining) of FT282-EV and FT282-BORIS cells. (C)The average 
proportion of cells in G1, S, or G2/M for 4 replicates and the individual values for each 
replicate are shown. Statistical analysis was done using an unpaired student’s t test. (D) 
Approximately 5 X 104 cells in 500 μl serum-free medium were pipetted into the top of 
transwell inserts in a 24 well plate with the lower chamber contained 500 μl complete 
medium. After incubation for 18hr, the membranes were washed, fixed and stained with 
crystal violet. Representative microphotographs of the bottom surface of the membranes are 
shown (left). The average number of cells on the bottom surface of the membrane was 
determined by microscopic examination of 3 biological replicates (four 20x fields each, right 
panel). Statistical analysis was done using an unpaired student’s t test. (E) Invasion assays 
were done in a manner similar to the transwell motility assays but using inserts coated with 
Matrigel. The number of cells per 20x field represents the mean and SD of 3 biological 
replicates (four 20x fields per replicate). Statistical analysis was done using an unpaired 
student’s t test.
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Figure 3. Ectopic expression of BORIS in FT282 cells induces gene expression changes in 
biological processes associated with cancer
(A) RNA-seq was carried out on FT282-EV and FT282-BORIS cells using 3 independent 
RNA isolates each. Differentially expressed genes between FT282-EV and FT282-BORIS 
cells (q-value < 0.05 and the log2 fold change > ± 0.25) were used to generate the heat map. 
(B) Bar plots of GO analysis. The length of the bar indicates the number of DEGs in each 
enriched category and the color of each bar indicates the adjusted p-value for each ontology. 
(C&D) RT-qPCR results for 6 genes corresponding to upregulated GO categories (C) and 3 
genes for downregulated categories (D). For each gene there were 3 “biological” replicates 
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(i.e. 3 cell cultures, 3 RNA preps, 3 cDNA syntheses) and 3 technical replicates biological 
replicate. The plots show the mean expression level in FT282-BORIS cells relative to 
FT282-EV cells and SE of the 3 biological replicates; the solid dots are the individual 
replicates. Statistical analysis was by unpaired t-test.
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Figure 4. Increased motility and invasion induced by ectopic expression of BORIS is partially 
attributable to increased expression of GALNT14.
(A) Western blot analysis of FT282-EV and FT282-BORIS cells using antibodies for 
GALNT14 and β-actin. (B) Western blot of FT282-BORIS cells 48 hr after transfection with 
Silencer® Select Negative Control 1 (scrambled) siRNA or Silencer® Select siRNA targeted 
against GALNT14. (C) Transwell migration assays were carried out as described in the 
legend to Figure1 using FT282-BORIS cells treated with scrambled siRNA control or 
GALNT14 siRNA. The average number of cells on the bottom surface of the membrane was 
determined by microscopic examination of 3 biological replicates (four 20x fields each). 
Statistical analysis was done using an unpaired student’s t test. (D) Invasion assays were 
carried out as described in the legend to Figure1 using FT282-BORIS cells treated with 
scrambled siRNA control or GALNT14 siRNA. The number of cells per 20x field represents 
the mean and SD of 3 biological replicates (four 20x fields per replicate). Statistical analysis 
was done using a t test.
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Figure 5. Ectopically expressed BORIS binds to a subset of CTCF sites enriched in > 1 CTCF 
binding motif.
(A) Left, Venn diagram depicting overlap of CTCF and BORIS binding sites in FT282-
BORIS cells determined by ChIP-seq. Right, Heatmap depicts CTCF (red) and BORIS 
(blue) occupancy at 55061 loci in FT282-BORIS cells. The tag density of CTCF and BORIS 
ChIP-seq data was collected within a 4-kb window around the summit of CTCF 
(CTCF&BORIS and CTCF-only) and BORIS peaks (BORIS-only). The collected data were 
subjected to k-means clustering using linear normalization based on similar tag density 
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profiles using seqMiner. (B) Left, Heat map showing ChIP-seq tag density at the top 1000 
CTCF-only, BORIS-only, and CTCF/BORIS peaks chosen for CTCF motif analysis. Right, 
Proportion of peaks in each class found by FIMO (MEME suite) to contain > 1 CTCF motif. 
Statistical analysis by Chi-squared test. (C) Genomic distribution of the three classes of 
CTCF and BORIS binding sites in FT282 cells ectopically expressing BORIS. (D) 
Prevalence of CTCF and BORIS binding sites at CpG islands in FT282-BORIS cells. (E). 
Proportions of differentially expressed genes bound by BORIS FT282-BORIS cells. 
Comparisons tested for significance by Chi Square analysis. (F) The GALNT14 locus shows 
enhancement of CTCF binding at its promoter and the appearance of a “new” CTCF binding 
site associated with enhanced gene expression following binding of BORIS.
Hillman et al. Page 25
Mol Cancer Res. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
